RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.722
+0.002 (+0.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.720
Open0.736
Bid0.000 x 1300
Ask0.000 x 4000
Day's Range0.700 - 0.736
52 Week Range0.630 - 1.600
Volume94,037
Avg. Volume482,083
Market Cap75.319M
Beta1.72
PE Ratio (TTM)N/A
EPS (TTM)-0.956
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.70
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust — Future Expectations, Projections Moving into 2018

    NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus ...

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT

    Q1 2018 Regulus Therapeutics Inc Earnings Call

  • Associated Press14 days ago

    Regulus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 15 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress
    PR Newswire14 days ago

    Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress

    Two pre-clinical programs advance towards clinical candidates Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , May 10, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical ...

  • Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018
    PR Newswire21 days ago

    Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018

    Regulus will host a conference call and webcast on May 10, 2018 at 5:00pm Eastern Time to discuss first quarter 2018 financial results and provide a general business update.  A live webcast of the call will be available online at www.regulusrx.com.  To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 8993969. To access the replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), conference ID 8993969. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic, and central nervous systems diseases.

  • Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
    PR Newswire24 days ago

    Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD

    LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated a Phase I multiple ascending dose (MAD) study in healthy volunteers for RGLS4326 for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. "We are pleased to advance the RGLS4326 program with the initiation of the MAD study, which will allow us to further characterize the safety and pharmacokinetic profile of RGLS4326 and establish the dose range that we will study in patients with ADPKD," said Timothy Wright, M.D., Chief R&D Officer of Regulus.

  • Kathryn J. Collier Joins Regulus Board of Directors
    PR Newswirelast month

    Kathryn J. Collier Joins Regulus Board of Directors

    LA JOLLA, Calif., April 17, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the Company's board of directors. "I am honored to join the Regulus board and look forward to bringing my strategic, financial, and operational experience and expertise to serve Regulus' board and management," said Kate Collier.

  • Regulus to Present at the Needham Healthcare Conference
    PR Newswire2 months ago

    Regulus to Present at the Needham Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT

    Q4 2017 Regulus Therapeutics Inc Earnings Call

  • Associated Press3 months ago

    Regulus reports 4Q loss

    The San Diego-based company said it had a loss of 14 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...

  • Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
    PR Newswire3 months ago

    Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update

    Full enrollment of RG-012 studies anticipated in 2H 2018 RGLS4326 Phase I study on track Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , March 7, 2018 /PRNewswire/ -- Regulus Therapeutics Inc ...

  • ACCESSWIRE3 months ago

    Regulus Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Regulus Therapeutics Inc. (NASDAQ: RGLS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 5:00 PM Eastern ...

  • Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?
    Simply Wall St.3 months ago

    Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?

    When Regulus Therapeutics Inc (NASDAQ:RGLS) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • Regulus to Present at the Cowen and Company 38th Annual Health Care Conference
    PR Newswire3 months ago

    Regulus to Present at the Cowen and Company 38th Annual Health Care Conference

    A live webcast of the presentation can be accessed on the Investors page of the Regulus website at www.regulusrx.com.  An archived replay of the webcast will be available on the Company's website after the conference. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, March 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018
    PR Newswire3 months ago

    Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018

    Regulus will host a conference call and webcast on March 7, 2018 at 5:00pm Eastern Time to discuss fourth quarter 2017 financial results and provide a general business update.  A live webcast of the call will be available online at www.regulusrx.com.  To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 4794278. To access the replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), conference ID 4794278. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic, and central nervous systems diseases.

  • WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration
    PR Newswire3 months ago

    WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

    Agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the USA SHANGHAI , Feb. 22, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec group company ...

  • Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
    PR Newswire3 months ago

    Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • PR Newswire5 months ago

    Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

    LA JOLLA, Calif. , Dec. 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT

    Q3 2017 Regulus Therapeutics Inc Earnings Call

  • Associated Press7 months ago

    Regulus reports 3Q loss

    The San Diego-based company said it had a loss of 18 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also ...

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks8 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

  • Regulus to Present at the 2017 Wells Fargo Healthcare Conference
    PR Newswire9 months ago

    Regulus to Present at the 2017 Wells Fargo Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
    Zacks9 months ago

    Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

    Investors in Regulus Therapeutics Inc. (RGLS) need to pay close attention to the stock based on moves in the options market lately.